Taken together, METTL14 suppresses p53‐WT CRC progression by inhibiting glycolysis through miR‐6769b‐3p/SLC2A3 and miR‐499a‐3p/PGAM1 pathways. This evidence concerns the gene SLC2A3 and colorectal carcinoma.